Construction of the vessel-collateral theory and its guidance for prevention and treatment of vasculopathy

Abstract

According to the self-discipline of traditional Chinese medicine, vessel-collateral theory was constructed systematically, which was important to improving prevention and treatment level of vasculopathy. The hypothesis of “homeostasis (Cheng), compensatory auto-adaptation (Zhi), regulation (Tiao) and equilibrium (Ping)” based on the “qi–yin-yang–five elements” coupled with the ying (nutrients)-wei (defense) theory, has become the core content of the vessel-collateral theory. Clinical and laboratory trials have been developed to further confirm the scientific connotations of the hypothesis, such as Tong Xin Luo capsule, as the representative drugs of vessel collateral theory, showed good efficacy in protecting the vascular endothelium, stabilizing the vulnerable plaque and reducing the blood vessel spasm. “Sou, ti, shu, tong” was the characteristics of Tong Xin Luo capsule in treating “microvascular damage” as the core mechanism of acute myocardial infarction, cerebral infarction and microvascular complications of diabetes. Shen Song Yang Xin capsules in the treatment of arrhythmia have made integrated adjustment advantage. Qi Li Qiang Xin capsules have been made treating both manifestation and root cause of chronic heart failure. These research have improved prevention and treatment level of major vascular system diseases.

Keywords

vessel-collateral theory / vasculopathy / prevention and treatment

References

[1] Jia ZH, Wu YL, Gao HL, Gu CH, Yuan GQ, Wu XC, Wei C. Pattern identification criteria for “vessel-vascular system diseases”. J Tradit Chin Med (Zhong Yi Za Zhi) 2007; 48(11): 1027-1032(in Chinese)

[2] Jia ZH, Gao HL, Gu CH, Yuan GQ, Wu XC, Wei C. Research on common pathogenesis of vessel diseases of 3469 patients based on TCM syndrome distribution. J Tradit Chin Med(Zhong Yi Za Zhi) 2009; 50(10): 920-924(in Chinese)

[3] Wang H, He ZQ, Liu X, Chen W, Zhou WQ, Liang C, Wu ZG. Vascular intimal and adventitia injuries in atherogenesis and signal transduction mechanism: a comparative study. Shanghai Med J(Shang Hai Yi Xue) 2009; 32(4): 293-295(in Chinese)

[4] Liu Y, Tang YX, Liang C, Wu ZG. Tongxinluo inhibits formation of vascular adventitia damage-induced atherosclerotic plaques and CD40 expression in rabbits. Shanghai Med J (Shang Hai Yi Xue) 2007; 30: 88-89(in Chinese)

[5] Zhang L, Liu Y, Lu XT, Wu YL, Zhang C, Ji XP, Wang R, Liu C X, Feng JB, Jiang H, Xu XS, Zhao YX, Zhang Y.Traditional Chinese medication Tongxinluo dose-dependently enhances stability of vulnerable plaques: a comparison with a high-dose simvastatin therapy. Am J Physiol Heart Circ Physiol 2009;297(6): H2004-H2014

[6] Karalliedde LD, Kappagoda CT. The challenge of traditional Chinese medicines for allopathic practitioners. Am J Physiol Heart Circ Physiol 2009; 297(6): H1967-H1969

[7] Guan QG, Cheng Y, Zeng DY, Sun XZ, He XZ, Han FT, Zhou XC, Miao ZL, Zhang L. Development of coronary artery atherosclerosis and coronary artery spasm model in Chinese mini-swine mediated by interleukin-1β. Chin J Arterioscler (Zhongguo Dong Mai Ying Hua Za Zhi) 2008; 28(7): 627-631(in Chinese)

[8] Guan QG, Zeng DY, Sun XZ, Zhou XC, Cheng Y, Miao ZL, He XZ, Han FT, Zhang L. Inhibitory effect and acting mechanism of Tongxinluo on IL-1β-mediated coronary intimal hyperplasia and 5-hydroxytryptamine-induced coronary vasospasm in small swine. Chinese J Integr Tradi West Med (Zhongguo Zhong Xi Yi Jie He Za Zhi) 2008; 28(7): 627-631(in Chinese)

[9] Duan L, Yang YJ, Zhang HT, Cheng YT, Kang S, Zhao JL, Meng L, Tian Y, Ye Y, Meng XM. Protective effect of Tongxinluo on mini-swine model of acute myocardial infarction and reperfusion damaged by oxidative stress. Chin J Pathophysiol (Zhongguo Bing Li Sheng Li Za Zhi) 2010; 26(3): 430-434(in Chinese)

[10] Cheng YT, Yang YJ, Zhang HT, Qian HY, Zhao JL, Meng XM, Luo FL, Wu YL. Pretreatment with Tongxinluo protects porcine myocardium from ischaemia/reperfusion injury through a nitric oxide related mechanism. Chin Med J (Engl) 2009; 122(13): 1529-1538

[11] Li XD, Yang YJ, Geng YJ, Jin C, Hu FH, Zhao JL, Zhang HT, Cheng YT, Qian HY, Wang LL, Zhang BJ, Wu YL. Tongxinluo reduces myocardial no-reflow and ischemia-reperfusion injury by stimulating the phosphorylation of eNOS via the PKA pathway. Am J Physiol Heart Circ Physiol 2010; 299(4): H1255-H1261

[12] Zhang CY, Zou JJ, Shi YS, Xia L, Wang HQ, Chen F, Liu ZM. Inhibitory effect of Tongluo recipe on glomerular endothelium proliferation in diabetic rats. Academic J Second Mil Med Univ(Di Er Jun Yi Da Xue Xue Bao) 2009; 30(6): 727-730 (in Chinese)

[13] Liu Y, Zou JJ, Li WT, Li X, Xia PJ, Sun LL, Zhang CY, Liu ZM. Protective effect of Tongluo recipe on diabetic nephropathy and its mechanism. Academic J Second Mil Med Univ (Di Er Jun Yi Da Xue Xue Bao) 2007; 28(3): 281-285 (in Chinese)

Acknowledgments

This work was supported by National Basic Research Program of China (973 Program) (No.2005CB523301) and Major Creation of New Drugs during the 11th Five-Year Plan Period (No. 2009ZX09313-003).

RIGHTS & PERMISSIONS

2014 Higher Education Press and Springer-Verlag Berlin Heidelberg